Biotech 101: How the US turned biotechnology into a $1 trillion industry

ChinaTalk interviewed the Chair and Vice Chair of the National Security Commission on Emerging Biotechnology .

Jason Kelly , the Chair, is the CEO of Ginkgo Bioworks , a publicly traded firm that provides a horizontal platform for cell programming.

Michelle Rozo , the Vice Chair, also serves as Vice President of Technical Capabilities at In-Q-Tel, and she previously held positions in Biden ’s NSC , the Department of Defense , and on the Hill .

Genentech developed the technology to make E. coli bacteria that made human insulin to give to juvenile diabetics.

Biotechnology was made possible by three underlying technologies: PCR , restriction enzymes, and biological knowledge about the operon.

The US government is the only source of funding for basic biology research, says Jason Kelly .

Jason Kelly : AI has the potential to have a bigger impact in biotechnology than it has in everyday life.

He says it's a huge opportunity for industry, for scientists, and for the U.S. It's worth remembering that this technology is very cheap and self-repairing. If you cut your skin, it fixes itself. Do we have other materials like that?.